质子束治疗的保险审批及其对治疗延迟的影响
单中心回顾性分析2015至2018年444例考虑质子束治疗的患者,其中成人396例、儿童48例。成人需预授权者64%初诊被拒、申诉后32%仍被拒,申诉导致治疗启动平均延迟3周(最长4个月),19%被拒患者完全放弃放疗。结论认为成人预授权要求构成显著负担并造成治疗延迟。
要点
- 成人需预授权者64%初诊被拒,申诉后32%仍被拒。
- 申诉导致治疗启动平均延迟3周(最长4个月),19%被拒患者放弃放疗。
- 3年间初诊拒绝率从55%升至74%(P = .034)。
核心结论
- 成人预授权要求对启动质子束治疗构成显著负担,并造成患者诊疗的显著延迟。
- 保险审批具有随意性,且随时间推移变得更加严格,与国家临床实践指南不一致。
- 付款方与提供方应寻求简化覆盖政策,与既定指南保持一致,以确保适当且及时的患者诊疗。
研究设计与样本
- 单中心回顾性分析,纳入2015年至2018年在一家美国国家癌症研究所指定的综合癌症中心考虑质子束治疗的所有患者,共444例,包括396例成人和48例儿童。
- 比较不同时间的治疗启动时间与拒绝率差异,并使用多变量逻辑回归识别初诊拒绝的预测因素。
主要发现
- 美国放射肿瘤学会模型政策支持该队列中77%患者的质子束治疗覆盖。
- 需要预授权的成人患者中,64%初诊被拒,申诉后32%仍被拒。
- 考虑再照射或随机3期试验入组的患者中,初诊拒绝率分别为57%和64%。
- 多变量分析中,保险覆盖与保险类别相关(P < .001),与诊断、再照射、试验入组或美国放射肿瘤学会模型政策指南无关。
- 3年期间初诊拒绝率从55%升至74%(P = .034);需要申诉者治疗启动平均延迟3周(最长4个月)(P < .001),19%被拒患者完全放弃放疗。
关键数值与推荐
- 美国放射肿瘤学会模型政策支持该队列中77%患者的质子束治疗覆盖。
- 需要预授权的成人患者初诊拒绝率为64%,申诉后仍被拒率为32%。
- 考虑再照射者初诊拒绝率为57%,考虑随机3期试验入组者为64%。
- 3年间初诊拒绝率从55%升至74%(P = .034)。
- 需要申诉者治疗启动平均延迟3周(最长4个月)(P < .001),19%被拒患者完全放弃放疗;儿童患者初诊拒绝率9%,申诉后全部获批,治疗启动未延迟(P = .47)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prior authorization (PA) has been widely implemented for proton beam therapy (PBT). We sought to determine the association between PA determination and patient characteristics, practice guidelines, and potential treatment delays. METHODS AND MATERIALS: A single-institution retrospective analysis was performed of all patients considered for PBT between 2015 and 2018 at a National Cancer Institute-designated Comprehensive Cancer Center. Differences in treatment start times and denial rates over time were compared, and multivariable logistic regression was used to identify predictors of initial denial. RESULTS: A total of 444 patients were considered for PBT, including 396 adult and 48 pediatric patients. The American Society for Radiation Oncology model policy supported PBT coverage for 77% of the cohort. Of adult patients requiring PA, 64% were initially denied and 32% remained denied after appeal. In patients considered for reirradiation or randomized phase 3 trial enrollment, initial denial rates were 57% and 64%, respectively. Insurance coverage was not related to diagnosis, reirradiation, trial enrollment, or the American Society for Radiation Oncology model policy guidelines, but it was related to insurance category on multivariable analysis (P < .001). Over a 3-year timespan, initial denial rates increased from 55% to 74% (P = .034). PA delayed treatment start by an average of 3 weeks (and up to 4 months) for those requiring appeal (P < .001) and resulted in 19% of denied patients abandoning radiation treatment altogether. Of pediatric patients, 9% were initially denied, all of whom were approved after appeal, and PA requirement did not delay treatment start (P = .47). CONCLUSIONS: PA requirements in adults represent a significant burden in initiating PBT and cause significant delays in patient care. Insurance approval is arbitrary and has become more restrictive over time, discordant with national clinical practice guidelines. Payors and providers should seek to streamline coverage policies in alignment with established guidelines to ensure appropriate and timely patient care.
引用
- Gupta A, Khan AJ, Goyal S, et al. Insurance Approval for Proton Beam Therapy and its Impact on Delays in Treatment. Int J Radiat Oncol Biol Phys. 2018. PMID: 30557673. doi:10.1016/j.ijrobp.2018.12.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。